Merck’s $200m patent damages award voided after “misconduct”
Northern District of California judge rules Merck forfeited its right to assert patents against Gilead because of "unclean hands" and "numerous unconscionable acts", voiding the second-largest US patent damages award of 2016 so far
A California federal judge has ruled that Merck forfeited its right to assert its Hepatitis C drug patents against Gilead because of "unclean hands," and voided the $200 million jury verdict that was awarded to Merck in March.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.